{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.0","upperLimit":"34.2","value":"26.6"},{"groupId":"OG001","lowerLimit":"12.3","upperLimit":"101.0","value":"25.8"},{"groupId":"OG002","lowerLimit":"20.8","upperLimit":"35.3","value":"28.1"},{"groupId":"OG003","lowerLimit":"9.7","upperLimit":"64.0","value":"17.0"},{"groupId":"OG004","lowerLimit":"12.1","upperLimit":"62.4","value":"16.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Apparent oral clearance (CL/F) was estimated using a non-compartmental method.","dispersionType":"Full Range","groups":[{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Stratum I, Dose Level 1 (50 mg/m2)"},{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Stratum I, Dose Level 2 (75 mg/m2)"},{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 95 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Stratum I, Dose Level 3 (95 mg/m2)"},{"description":"Heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Stratum II, Dose Level 1 (50 mg/m2)"},{"description":"Heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Stratum II, Dose Level 2 (75mg/m2)"}],"paramType":"MEDIAN","populationDescription":"Patients with blood samples collected for pharmacokinetic studies on days 21-22 of course 1 were included.","reportingStatus":"POSTED","timeFrame":"Up to day 22","title":"Steady State Apparent Oral Clearance (CL/F)","type":"PRIMARY","unitOfMeasure":"L/h/m^2"}